Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/14/14  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Mark McKeage

Wrong Dr. Mark McKeage?
 
Background

Employment History

  • Associate Professor In Clinical Pharmacology
    The University of Auckland
  • Co-Director, Associate Professor
    Auckland Cancer Centre
  • Key Investigator
    University of Auckland , New Zealand
  • Member, AS1404 Lung Cancer Study
    University of Auckland , New Zealand
  • Associate Professor In Clinical Pharmacology
    University of Auckland , New Zealand
  • Auckland Theatre Company

Education

  • Ph.D.
53 Total References
Web References
"Through the current Phase 1b study ...
www.digitalproducer.com, 14 May 2014 [cached]
"Through the current Phase 1b study in NSCLC and prior Phase 1 trials of demcizumab we have learned much about its safety and anti-tumor properties," said Mark McKeage, MBChB, MMedSc, Ph.D., FRACP, University of Auckland.
...
Presenting author: Mark McKeage, MBChB, MMedSc, Ph.D., FRACP, University of Auckland
Associate Investigators | Maurice Wilkins Centre
www.mauricewilkinscentre.org, 8 April 2014 [cached]
Associate Professor Mark McKeage
Department of Pharmacology - The University of Auckland
"Bevacizumab, however, predominantly ...
www.eurekalert.org, 12 Jan 2010 [cached]
"Bevacizumab, however, predominantly interferes with the formation of new blood vessels," said lead researcher Mark McKeage, Ph.D., an associate professor in clinical pharmacology at the University of Auckland.
...
New targeted therapies and chemotherapies have been evaluated, but many show little promise as first-line treatments in patients with this type of cancer," said McKeage.
McKeage and colleagues evaluated 108 patients with stage IIIb/IV NSCLC.
Local cancer drug approved for first clinical trial in United States and New Zealand | Maurice Wilkins Centre
www.mauricewilkinscentre.org, 30 Aug 2012 [cached]
For the first time we will be screening patients for the genetic mutation that causes drug resistance and then enrolling them in a trial of a New Zealand drug designed to target that mutation," says ACSRC Co-Director, Associate Professor Mark McKeage, the Clinical Oncologist leading the Auckland City Hospital trial, referring to the phase II part of the phase I/II trial.
...
Drs Jeff Smaill and Adam Patterson, Professor Bill Denny and Associate Professor Mark McKeage are all Maurice Wilkins Centre investigators.
Antisoma plc - Positive survival data from ASA404 trial presented at World Conference on Lung Cancer
www.antisoma.com, 5 Sept 2007 [cached]
Dr Mark McKeage of the University of Auckland, New Zealand, an investigator in both ASA404 lung cancer trials and the presenter of the new data in Korea, said: "This is a second set of positive data on ASA404 in lung cancer.
Other People with the name "McKeage":
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304